SCH: collaborative and grounded AL agents for accountable BACTEREMIA decision - bloodstream infections (BACTEREMIA) are a frequent precursor to sepsis, a leading cause of in-hospital mortality in…
Active Grant Awarded
- Award ID
- R01AI206896
- Recipient
-
The University Of Central Florida Board Of Trustees UEI RD7MXJV7DKT9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,751
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 5% complete
- Place of performance
- Orlando, FL 32826, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded The University of Central Florida Board of Trustees $299,751 on September 9, 2026, under Grant R01AI206896 in Assistance Listing 93.855, Allergy and Infectious Diseases Research. The award funds development and validation of an end-to-end, physician-centered AI system for bacteremia diagnosis and treatment, intended to improve accuracy, equity, and safety and to reduce sepsis mortality. Aim 1 builds a role-aligned multi-agent architecture whose specialized agents mirror clinical roles (triage, risk stratification, contamination discrimination, organism and antibiogram interpretation, culture allocation, and therapy recommendation), coordinated by a critic and self-refinement agent that detects contradictions, propagates uncertainty, and produces calibrated recommendations. Aim 2 establishes knowledge-grounded reasoning through a hybrid graph- and vector-based retrieval framework with patient-state anchoring and temporal weighting, with interfaces that let clinicians inject decision rules and enforce safety constraints. Aim 3 builds a framework for multi-site verification, fairness testing, domain-shift adaptation, and privacy-preserving deployment that maintains accuracy across diverse populations while complying with HIPAA. The period of performance ends August 31, 2030, and work is performed in Orlando, FL 32826, USA.
Description
SCH: collaborative and grounded AL agents for accountable BACTEREMIA decision - bloodstream infections (BACTEREMIA) are a frequent precursor to sepsis, a leading cause of in-hospital mortality in the united states and worldwide. Their management depends on a multi-step workflow: risk stratification, contamination discrimination, organism and resistance identification, blood-culture allocation, and antibiotic selection, handled by different clinical roles. Current processes are slow, costly, prone to contamination, and inconsistently supported by computational tools. Existing artificial intelligence (AI) systems address isolated steps, lack transparency, and are rarely validated across sites, limiting clinical adoption. The broad, long-term objective of this project is to develop and validate an end-to-end, physician-centered AI system that improves the accuracy, equity, and safety of BACTEREMIA diagnosis and treatment, thereby reducing sepsis mortality and strengthening antimicrobial stewardship. The project pursues three specific aims. Aim 1 will develop a role-aligned multi-agent architecture whose specialized agents mirror clinical roles "triage, risk stratification, contamination discrimination, organism and antibiogram interpretation, culture allocation, and therapy recommendation" coordinated by a critic and self-refinement agent that detects contradictions, propagates uncertainty, and produces calibrated recommendations. Aim 2 will establish knowledge-grounded, physician-incorporated reasoning through a hybrid graph- and vector-based retrieval framework with patient-state anchoring and temporal weighting that adapts to evolving resistance, with interfaces that let clinicians inject decision rules and enforce safety constraints. Aim 3 will build a framework for multi-site verification, fairness testing, domain-shift adaptation, and privacy-preserving deployment that maintains accuracy across diverse populations while complying with hipaa. Methods integrate large language model-based agents, reinforcement learning from clinician feedback, retrieval-augmented generation, domain-shift recalibration, and privacy-preserving computation. The system will be evaluated on public and DE-identified, IRB-approved clinical data using discrimination, calibration, fairness, consistency, and usability measures, including silent-mode prospective testing, to deliver reliable, explainable, and verifiable decision support for bloodstream infections.
Quick answers
Who received award R01AI206896?
R01AI206896 was awarded to The University Of Central Florida Board Of Trustees by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.
How much is award R01AI206896 worth?
$299,751 has been obligated on R01AI206896.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award